Reversible Cancer Therapeutics-related Cardiac Dysfunction Complicating Intra-cardiac Thrombi

Shingo Tsujinaga, Hiroyuki Iwano, Tomohiro Oshino, Takahide Kadosaka, Yoshifumi Mizuguchi, Ko Motoi, Yasuyuki Chiba, Taro Koya, Taro Temma, Kiwamu Kamiya, Arata Fukushima, Takuya Koizumi, Sakae Takenaka, Atsushi Tada, Suguru Ishizaka, Miwa Sarashina, Kazunori Omote, Rui Kamada, Takao Konishi, Takuma Sato, Toshiyuki Nagai, Hiroko Yamashita, and Toshihisa Anzai

Abstract:
Epirubicin-based chemotherapy carries a risk of inducing heart failure, although the frequency is rare. Bevacizumab, an anti-vascular endothelial growth factor monoclonal antibody, has recently been widely used in patients with recurrent breast cancer as a first-line chemotherapeutic agent. Heart failure or arterial thromboembolism has been reported as a rare cardiovascular complication of bevacizumab. We herein report a breast cancer patient with reversible cancer therapeutics-related cardiac dysfunction associated with bevacizumab and epirubicin complicating intracardiac thrombi in the left atrium and left ventricle. This case underscores the importance of tailored medical planning according to the individual status in patients receiving anti-cancer therapies.

Key words: epirubicin, bevacizumab, cardiotoxicity, heart failure, thrombus

(Intern Med 59: 2155-2160, 2020)
(DOI: 10.2169/internalmedicine.4792-20)

Introduction
Anthracycline, including epirubicin-based chemotherapy, improves the survival of breast cancer patients but is associated with an increased risk of heart failure (1).

In recent years, systemic therapy targeting vascular endothelial growth factor (VEGF) and its receptors has proven to be a successful strategy in patients with cancer. Bevacizumab is a widely used anti-VEGF monoclonal antibody targeting the VEGF ligand. Although it has been shown to improve clinical outcomes in several malignancies including advanced breast cancer (2), its use has been associated with many cardiovascular events (3-5).

We herein report a breast cancer patient with reversible cancer therapeutics-related cardiac dysfunction associated with bevacizumab along with epirubicin complicated by intracardiac thrombi in the left atrium and left ventricle.

Case Report
A 65-year-old woman with a history of postoperative chemotherapy for right breast cancer was referred to our department due to congestive heart failure. The breast cancer had been graded as clinical stage IIa, triple-negative invasive ductal carcinoma [estrogen receptor 0%, progesterone receptor 0%, and human epidermal growth factor receptor 2 (HER2) immunohistochemistry 0%], and the Ki-67-positive cell index was 98.6%. She had received 4 courses of epirubicin (total dose: 327 mg/m²) and cyclophosphamide (total dose: 2,183 mg/m²) followed by paclitaxel (total dose: 727 mg/m²) and bevacizumab (total dose: 546 mg/m²).

Nine months after the end of epirubicin administration and three months after the end of bevacizumab administration, she developed dyspnea on exertion despite denying any history of cardiovascular diseases. Three months later, car-
diac enlargement with pleural effusion and intracardiac thrombi were detected by contrast-enhanced computed tomography (CT). Subsequently, she was introduced to our department and admitted for the management of heart failure and intracardiac thrombi.

On admission, she showed a blood pressure of 150/101 mmHg, pulse rate of 102/min, and transcutaneous oxygen saturation of 98% in room air. A clinical examination revealed jugular vein distension, third heart sound, and abdominal fullness. Chest X-ray showed lung congestion with apparent cardiomegaly and pleural effusion (Fig. 1A). The electrocardiogram showed sinus tachycardia with complete right bundle branch block (Fig. 1B). The serum N-terminal-pro-B-type natriuretic peptide (NT-pro-BNP) level was markedly increased to 7,648 pg/mL. Transthoracic echocardiography showed diffuse severe hypokinesis of the left ventricular (LV) wall [ejection fraction (EF): 24%] with a mildly enlarged cavity and LV hypertrophy (Fig. 2A). Mural thrombus with a radius of 2 cm was observed in not only the LV apex but also the left atrium (Fig. 2B, C), which was confirmed by contrast-enhanced CT taken after admission (Fig. 3A, B). The patient was diagnosed with heart failure caused by cancer therapeutics-related cardiac dysfunction (CTRCD), and intravenous carperitide (0.025 μg/kg/min) and furosemide (40 mg/day) were initiated along with unfractionated heparin to maintain an activated partial thromboplastin time of 60 seconds followed by warfarin.

Soon after the infusion therapy, the congestion was relieved, and medication was switched to oral cardioprotective drugs, such as enalapril (up to 2.5 mg/day) and carvedilol (up to 10 mg/day). A coronary angiogram performed at the 10th day showed no coronary artery lesions, and the pathological findings in an endomyocardial biopsy specimen obtained from the right side of the interventricular septum showed mild cardiomyocyte hypertrophy and no myocardial fibrosis or findings specific for secondary cardiomyopathy. Anticoagulation therapy with warfarin was continued in order to maintain a prothrombin time international normalized ratio ≥2.0, resulting in the disappearance of the intracardiac thrombi on echocardiography on the 19th day without any thromboembolic events. As a result, the patient was discharged on the 32nd day without any residual cardiovascular symptoms.

Despite the favorable course of cardiovascular disease, local recurrence of breast cancer was found thereafter, and reoperation was performed 52 days after the discharge without any cardiovascular events. Nevertheless, lymph node metastasis was found two months after the reoperation. Accordingly, postoperative chemotherapy with capecitabine was planned. A repeat echocardiogram showed a reduction in the LV size and an increase in the LV EF to 52%, and contrast-enhanced CT showed no intracardiac thrombus. Because of the potential interaction of capecitabine with warfarin, we decided to discontinue warfarin based on the low estimated risk of recurrent thromboembolism thanks to the recovered cardiac function.

Eight months after discharge, chest-X ray showed normal findings in the heart (Fig. 4A), the serum NT-pro-BNP level had decreased to 89 pg/mL, and an echocardiogram showed a normal LV systolic function (LV EF: 63%) (Fig. 4B). Contrast-enhanced imaging confirmed no intracardiac thrombus (Fig. 4C). She is now receiving a new chemotherapy regimen with a low risk of cardiotoxicity.
Discussion

In the treatment of breast cancer, anthracyclines are established as a main component of cancer therapy regimens, even though they have dose-dependent cardiotoxicity. The incidence of heart failure after high-dose epirubicin exposure (approximately 900 mg/m$^2$) is known to exceed 5-10%, but substantial cardiotoxicity may occur at even lower doses, depending on the individual susceptibility (6). Heart failure due to epirubicin typically manifests within several years after exposure (7). However, anthracyclines can also cause myocardial injury in the acute (immediately after exposure) and subacute (within one year after exposure) phases, even though their frequencies are rare (acute: <1%; subacute: 1-6%) (8).

However, in recent years, anti-VEGF monoclonal antibodies, such as bevacizumab, have become one of the first-line therapies for human epidermal growth factor receptor type 2-positive breast cancers (2). The use of bevacizumab is associated with class-effect adverse events, including hypertension, arterial thromboembolism, and congestive heart failure (3, 4), and the incidence of clinically significant heart failure is reported to be approximately 2-4% (9). Cyclophosphamide also induces acute heart failure with an incidence of 2-17%, although this often occurs within 48 hours after the administration and sometimes within 2 or 3 weeks (10, 11). Cardiac toxicity caused by paclitaxel takes the form of sub-acute or acute bradycardia, heart block, and atrial or ventricular arrhythmia with an incidence of 0.5%, and paclitaxel itself does not induce heart failure (12).

In this particular patient, the time difference between the
occurrence of heart failure symptoms and the final course of epirubicin administration (9 months) and low amount of total use (327 mg/m²) suggest a relatively low probability of epirubicin-associated heart failure, although the patient might have suffered from epirubicin-induced subacute myocardial injury. As there were no data concerning cardiac biomarkers and echocardiography during epirubicin administration, the latter could not be completely denied. These findings, together with the short duration from the final course of bevacizumab administration to the onset of heart failure, suggested that bevacizumab was the main cause of the incidence of LV systolic dysfunction and subsequent
heart failure.

Bevacizumab therapy for breast cancer is reported to carry a substantially high risk of heart failure due to prior or concomitant exposure to other cardiotoxic medications (4). In addition, consistent with the typical manifestation of bevacizumab-associated heart failure (13), the present patient showed an elevated blood pressure and hypertrophied LV, which also suggested probability of bevacizumab-associated heart failure. Anthracyclines directly cause cell death, leading to irreversible myocyte destruction, even though anthracycline-induced subacute myocardial injury may occasionally be reversible when cardioprotective therapy is administered (14). In contrast, VEGF inhibitors alter the normal cellular function by affecting the mitochondrial system and reducing protein synthesis, leading to reversible myocyte destruction (5). Cyclophosphamide and paclitaxel were unlikely to be involved in heart failure in the present case, given the time course and their reported cardiac toxicity.

Fortunately, the patient was able to be successfully treated, and the LV systolic function recovered after standard therapy using angiotensin-converting enzyme inhibitors and beta blockers, which is recommended by the guidelines (15, 16).

In summary, the cause of cardiac dysfunction and heart failure in this case was considered to be CTRCD associated with bevacizumab along with epirubicin that showed a response to cardioprotective therapy. Importantly, the present case was complicated by intracardiac thrombi at the time of worsening heart failure. A case of epirubicin-associated heart failure with LV apical thrombus has been reported (17), and combination treatment of bevacizumab and anti-cancer agents is known to be associated with an increased risk of arterial thromboembolism, although the underlying mechanism remains unclear (5). Some researchers have suggested that bevacizumab might reduce the anti-inflammatory effects of VEGF exposure, leading to increased inflammation and thrombus formation (18). In addition to these agent-specific reasons, the hypercoagulation status during the decompensated heart failure and intracavity blood stasis due to severe LV and left atrial dysfunction may have been associated with thrombus formation, according to Virchow’s triad.

To our knowledge, this is the first report of reversible CTRCD associated with bevacizumab and epirubicin showing both left atrial and LV thrombus in a breast cancer patient. In addition, it is noteworthy that the thrombi were able to be managed using anticoagulation therapy, and the medication was ultimately able to be discontinued without any thromboembolic events owing to the recovered cardiac function, which aided in the management of her breast cancer. This was an educational case suggesting the importance of cardiology intervention in oncology and collaboration between cardiologists and oncologists.

**Conclusion**

We experienced a case of reversible CTRCD associated with bevacizumab along with epirubicin showing intracardiac thrombi in a breast cancer patient. This case emphasizes the importance of tailored medical planning according to the individual status in patients receiving anti-cancer therapies.

The authors state that they have no Conflict of Interest (COI).

**References**

1. Banke A, Fosbol EL, Moller JE, et al. Long-term effect of epirubicin on incidence of heart failure in women with breast cancer: insight from a randomized clinical trial. Eur J Heart Fail 20: 1447-1453, 2018.
2. Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 7: 332-344, 2007.
3. Scappaticci FA, Skilling RS, Holdén SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 99: 1232-1239, 2007.
4. Choueiri TK, Mayer EL, Je Y, et al. Congestive heart failure risk in patients with breast cancer treated with bevacizumab. Clin Oncol 29: 632-638, 2011.
5. Economopoulos P, Kotsakis A, Kapiris I, Kentepozidis N. Cancer therapy and cardiovascular risk: focus on bevacizumab. Cancer Manag Res 7: 133-143, 2015.
6. Ryberg M, Nielsen D, Cortese G, Nielsen G, Skovsgaard T, Andersen PK. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients. J Natl Cancer Inst 100: 1058-1067, 2008.
7. Fumoleau P, Roche H, Kerbrat P, et al. Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results. Ann Oncol 17: 85-92, 2006.
8. Wouters KA, Kremer LC, Miller TL, Herman EH, Lipshultz SE. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br J Haematol 131: 561-578, 2005.
9. Yeh ET, Tong AT, Lenihan DJ, et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 109: 3122-3131, 2004.
10. Katayama M, Imai Y, Hashimoto H, et al. Fulminant fatal cardiotoxicity following cyclophosphamide therapy. J Cardiol 54: 330-334, 2009.
11. Dhesi S, Chu MP, Blevins G, et al. Cyclophosphamide-Induced cardiomyopathy: a case report, review, and recommendations for management. J Investig Med High Impact Case Rep 1: 2324709613480346, 2013.
12. Schlitt A, Jordan K, Vordermark D, Schwamborn J, Langer T, Thomsen C. Cardiotoxicity and oncological treatments. Dtsch Arztebl Int 111: 161-168, 2014.
13. Chen MH, Kerkela R, Force T. Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics. Circulation 118: 84-95, 2008.
14. Cardinale D, Colombo A, Lamantia G, et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 55: 213-220, 2010.
15. Curigliano G, Cardinale D, Suter T, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol 23 (Suppl): vii155-viii166, 2012.
16. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure
2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 14: 803-869, 2012.

17. Okura Y, Kawasaki T, Kanbayashi C, Sato N. A case of epirubicin-associated cardiotoxicity progressing to life-threatening heart failure and splenic thromboembolism. Intern Med 51: 1355-1360, 2012.

18. Kuenen BC, Levi M, Meijers JC, et al. Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients. Arterioscler Thromb Vasc Biol 22: 1500-1505, 2002.

The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).